FTRE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

FT

Mkt Cap

$2.14B

Volume

1.48M

Next Earnings

October 29th

Loading chart

FT

FTREFortrea Holdings Inc. Common Stock

FTRE

Pay with—

Available Balance0.00

FT

Mkt Cap

$2.16B

Volume

1.48M

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

Fortrea Akan Mengakuisisi Unit Farmakologi Klinis dan Operasional Laboratorium Bionalitik dari Worldwide Clinical TrialsFortrea has signed a definitive agreement to acquire the Early Phase Services division from Worldwide Clinical Trials for approximately $45 million. The acquisition includes bioanalytical laboratories in Austin, a 200-bed clinical pharmacology unit in San Antonio, and biospecimen storage facilities in Pflugerville, Texas. This deal strengthens Fortrea's early-stage clinical development platform and integrated capabilities, while allowing Worldwide to focus on its faster-growing late-stage business across oncology, neuroscience, and rare diseases.GlobeNewswire Inc. · Sep 3, 2026

Fortrea Adquire Unidade de Farmacologia Clínica e Operações de Laboratório Bioanalítico da Worldwide Clinical TrialsFortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in cash. The acquisition includes a GLP-certified bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biosampling storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's early-stage clinical development platform and enables integrated Phase I-IV services, while allowing Worldwide to focus on its rapidly growing advanced-stage development business in oncology, neurociencia, and rare diseases.GlobeNewswire Inc. · Sep 3, 2026

フォートリア、ワールドワイド・クリニカル・トライアルズから臨床薬理部門およびバイオアナリシスラボ事業を買収Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical lab in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and a biorepository facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform from Phase I through Phase IV trials, while allowing Worldwide to focus on its rapidly growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.GlobeNewswire Inc. · Sep 3, 2026

Fortrea übernimmt Einheit für klinische Pharmakologie und bioanalytische Laboraktivitäten von Worldwide Clinical TrialsFortrea hat eine verbindliche Vereinbarung zum Erwerb des Geschäftsbereichs 'Frühe klinische Entwicklung' von Worldwide Clinical Trials für etwa 45 Millionen US-Dollar abgeschlossen. Die Übernahme umfasst ein GLP-konformes bioanalytisches Labor in Austin, eine klinisch-pharmakologische Abteilung mit 200 Betten in San Antonio und ein Bioprobenlager in Texas. Dies stärkt Fortreas Position als führender globaler Partner für klinische Entwicklung und ermöglicht integrierte Lösungen für frühe klinische Phasen.GlobeNewswire Inc. · Sep 3, 2026

Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical TrialsFortrea has agreed to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biological sample storage facility in Pflugerville, Texas. This strengthens Fortrea's end-to-end clinical development platform with integrated bioanalytical capabilities for both large and small molecules, while allowing Worldwide to focus on its growing advanced-stage development activities in oncology, neurosciences, internal medicine, and rare diseases.GlobeNewswire Inc. · Sep 3, 2026

Fortrea 将收购 Worldwide Clinical Trials 的临床药理部门和生物分析实验室业务Fortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in cash. The acquisition includes a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biosampling facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and early-stage capabilities, while allowing Worldwide to focus on its faster-growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.GlobeNewswire Inc. · Sep 3, 2026

Fortrea תרכוש את היחידה לפרמקולוגיה קלינית ואת פעילות המעבדה הביו-אנליטית של Worldwide Clinical TrialsFortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million in cash. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biological sample storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and early-stage capabilities, while allowing Worldwide to focus on its rapidly growing late-stage development business in oncology, neuroscience, internal medicine, and rare diseases.GlobeNewswire Inc. · Sep 3, 2026

Fortrea, Worldwide Clinical Trials의 임상약리 유닛·생물분석 연구소 사업 인수Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and biospecimen storage facilities in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform from Phase 1 through Phase 4 trials and post-approval evidence generation, while allowing Worldwide to focus on its faster-growing late-stage clinical business in oncology, neuroscience, internal medicine, and rare diseases.GlobeNewswire Inc. · Sep 3, 2026

Fortrea Akan Mengambil Alih Unit Farmakologi Klinikal dan Operasi Makmal Bioanalisis daripada Worldwide Clinical TrialsFortrea has signed a definitive agreement to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million. The acquisition includes a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biospecimen storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform and expands its early-phase capabilities, while allowing Worldwide to focus on its rapidly growing late-phase business in oncology, neuroscience, and rare diseases.GlobeNewswire Inc. · Sep 3, 2026

Fortrea 將收購 Worldwide Clinical Trials 的臨床藥理學部門及生物分析實驗室業務Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP bioanalytical lab in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biosampling facility in Frugerville, Texas. The deal strengthens Fortrea's end-to-end clinical development platform and early-stage capabilities, while allowing Worldwide to focus on its rapidly growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.GlobeNewswire Inc. · Sep 3, 2026

to start trading

FT

FTREFortrea Holdings Inc. Common Stock

FTRE

Pay with—

Available Balance0.00

Your PositionYou don't own any FTRE yet.

Related Tickers

Earnings